Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Non-Current Assets: 2023-2025

  • Zhengye Biotechnology Holding's Non-Current Assets was N/A to $41.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $41.9 million, marking a year-over-year change of. This contributed to the annual value of $43.2 million for FY2024, which is 1.61% down from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Non-Current Assets stood at $41.9 million for Q2 2025, which was down 3.08% from $43.2 million recorded in Q4 2024.
  • In the past 5 years, Zhengye Biotechnology Holding's Non-Current Assets ranged from a high of $43.2 million in Q4 2024 and a low of $41.9 million during Q2 2025.
  • Moreover, its 3-year median value for Non-Current Assets was $43.1 million (2023), whereas its average is $42.8 million.
  • Data for Zhengye Biotechnology Holding's Non-Current Assets shows a peak YoY grew of 0.24% (in 2024) over the last 5 years.
  • Over the past 3 years, Zhengye Biotechnology Holding's Non-Current Assets (Quarterly) stood at $43.1 million in 2023, then grew by 0.24% to $43.2 million in 2024, then reached $41.9 million in 2025.
  • Its Non-Current Assets was $41.9 million in Q2 2025, compared to $43.2 million in Q4 2024 and $43.1 million in Q4 2023.